{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T22:47:29Z","timestamp":1785538049446,"version":"3.56.0"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2022,5,13]],"date-time":"2022-05-13T00:00:00Z","timestamp":1652400000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,5,13]],"date-time":"2022-05-13T00:00:00Z","timestamp":1652400000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100010663","name":"H2020 European Research Council","doi-asserted-by":"publisher","award":["761104"],"award-info":[{"award-number":["761104"]}],"id":[{"id":"10.13039\/100010663","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drug Deliv. and Transl. Res."],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.1007\/s13346-022-01175-w","type":"journal-article","created":{"date-parts":[[2022,5,13]],"date-time":"2022-05-13T13:09:52Z","timestamp":1652447392000},"page":"2178-2186","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["A physiologically based pharmacokinetic model to predict pegylated liposomal doxorubicin disposition in rats and human"],"prefix":"10.1007","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2078-360X","authenticated-orcid":false,"given":"Maiara Camotti","family":"Montanha","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice","family":"Howarth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Doaa Ahmed","family":"Mohamed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Estelle","family":"Loier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren","family":"Main","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"R\u00f6sslein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christiaan","family":"Delmaar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adriele","family":"Prina-Mello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Siccardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,5,13]]},"reference":[{"key":"1175_CR1","first-page":"1","volume-title":"Pharmaceutical Nanotechnology: Innovation and Production [Internet]","author":"A Ari\u00ebn","year":"2016","unstructured":"Ari\u00ebn A, Stoffels P. History: potential, challenges, and future development in nanopharmaceutical research and industry. In: Pharmaceutical Nanotechnology: Innovation and Production [Internet]. Weinheim, Germany: Wiley-VCH Verlag GmbH & Co. KGaA; 2016. p. 1\u201316."},{"issue":"1","key":"1175_CR2","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1038\/sj.jim.2900673","volume":"23","author":"CR Hutchinson","year":"1999","unstructured":"Hutchinson CR, Colombo AL. Genetic engineering of doxorubicin production in Streptomyces peucetius: a review. J Ind Microbiol Biotechnol. 1999;23(1):647\u201352.","journal-title":"J Ind Microbiol Biotechnol"},{"key":"1175_CR3","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1002\/9783527800681.ch29","volume-title":"Pharmaceutical Nanotechnology: Innovation and Production [Internet]","author":"M Ashford","year":"2016","unstructured":"Ashford M. Development and Commercialization of Nanocarrier-Based Drug Products. In: Pharmaceutical Nanotechnology: Innovation and Production [Internet]. Weinheim, Germany: Wiley-VCH Verlag GmbH & Co. KGaA; 2016. p. 697\u2013734."},{"issue":"1\u20132","key":"1175_CR4","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/S0168-3659(99)00248-5","volume":"65","author":"H Maeda","year":"2000","unstructured":"Maeda H, Wu J, Sawa T, Matsumura Y, Hori K. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J Control Release. 2000;65(1\u20132):271\u201384.","journal-title":"J Control Release"},{"key":"1175_CR5","doi-asserted-by":"crossref","unstructured":"Bozzuto G, Molinari A. Liposomes as nanomedical devices. Int J Nanomedicine. 2015 Feb 975.","DOI":"10.2147\/IJN.S68861"},{"issue":"2","key":"1175_CR6","doi-asserted-by":"publisher","first-page":"113","DOI":"10.4155\/tde-2018-0062","volume":"10","author":"G Bor","year":"2019","unstructured":"Bor G, Mat Azmi ID, Yaghmur A. Nanomedicines for cancer therapy: current status, challenges and future prospects. Ther Deliv. 2019;10(2):113\u201332.","journal-title":"Ther Deliv"},{"issue":"2","key":"1175_CR7","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.jconrel.2012.03.020","volume":"160","author":"YC Barenholz","year":"2012","unstructured":"Barenholz YC. Doxil\u00ae \u2014 The first FDA-approved nano-drug: lessons learned. J Control Release. 2012;160(2):117\u201334.","journal-title":"J Control Release"},{"key":"1175_CR8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/bph.12604","volume":"171","author":"DM Moss","year":"2014","unstructured":"Moss DM, Siccardi M. Optimizing nanomedicine pharmacokinetics using physiologically based pharmacokinetics modelling. Br J Pharmacol. 2014;171:1\u201317.","journal-title":"Br J Pharmacol"},{"key":"1175_CR9","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1016\/j.csbj.2020.02.014","volume":"18","author":"P Dogra","year":"2020","unstructured":"Dogra P, et al. A mathematical model to predict nanomedicine pharmacokinetics and tumor delivery. Comput Struct Biotechnol J. 2020;18:518\u201331.","journal-title":"Comput Struct Biotechnol J"},{"key":"1175_CR10","doi-asserted-by":"publisher","DOI":"10.1002\/9781118140291","volume-title":"Physiologically-based pharmacokinetic (PBPK) modeling and simulations: principles, methods, and applications in the pharmaceutical industry","author":"SA Peters","year":"2012","unstructured":"Peters SA. Physiologically-based pharmacokinetic (PBPK) modeling and simulations: principles, methods, and applications in the pharmaceutical industry. John Wiley & Sons; 2012."},{"issue":"1","key":"1175_CR11","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1007\/s10928-011-9232-2","volume":"39","author":"DK Shah","year":"2012","unstructured":"Shah DK, Betts AM. Towards a platform PBPK model to characterize the plasma and tissue disposition of monoclonal antibodies in preclinical species and human. J Pharmacokinet Pharmacodyn. 2012;39(1):67\u201386.","journal-title":"J Pharmacokinet Pharmacodyn"},{"key":"1175_CR12","unstructured":"Brown R, Foran J, Olin S, Robinson D. Physiological parameter values for PBPK models. International Life Sciences Institute, and Risk Science Institute, Washington, USA; 1994."},{"key":"1175_CR13","unstructured":"Centers for Disease Control and Prevention. Available from: https:\/\/www.cdc.gov\/growthcharts\/clinical_charts.htm. Accessed 19 Apr 2022."},{"issue":"9","key":"1175_CR14","doi-asserted-by":"publisher","first-page":"751","DOI":"10.3109\/10408444.2012.709225","volume":"42","author":"S Bosgra","year":"2012","unstructured":"Bosgra S, et al. An improved model to predict physiologically based model parameters and their inter-individual variability from anthropometry. Crit Rev Toxicol. 2012;42(9):751\u201367.","journal-title":"Crit Rev Toxicol"},{"issue":"1","key":"1175_CR15","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1208\/s12248-015-9819-4","volume":"18","author":"KL Gill","year":"2016","unstructured":"Gill KL, Gardner I, Li L, Jamei M. A bottom-up whole-body physiologically based pharmacokinetic model to mechanistically predict tissue distribution and the rate of subcutaneous absorption of therapeutic proteins. AAPS J. 2016;18(1):156\u201370.","journal-title":"AAPS J"},{"issue":"1","key":"1175_CR16","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.xphs.2018.10.037","volume":"108","author":"D Yuan","year":"2019","unstructured":"Yuan D, He H, Wu Y, Fan J, Cao Y. Physiologically based pharmacokinetic modeling of nanoparticles. J Pharm Sci. 2019;108(1):58\u201372.","journal-title":"J Pharm Sci"},{"issue":"1","key":"1175_CR17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/2040-2384-2-14","volume":"2","author":"H Sarin","year":"2010","unstructured":"Sarin H. Physiologic upper limits of pore size of different blood capillary types and another perspective on the dual pore theory of microvascular permeability. J Angiogenes Res. 2010;2(1):1\u201319.","journal-title":"J Angiogenes Res"},{"key":"1175_CR18","first-page":"3365","volume":"8","author":"G Bachler","year":"2013","unstructured":"Bachler G, von Goetz N, Hungerb\u00fchler K. A physiologically based pharmacokinetic model for ionic silver and silver nanoparticles. Int J Nanomed. 2013;8:3365.","journal-title":"Int J Nanomed"},{"issue":"1","key":"1175_CR19","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1002\/jps.10005","volume":"91","author":"P Poulin","year":"2002","unstructured":"Poulin P, Theil FP. Prediction of pharmacokinetics prior to in vivo studies. 1. Mechanism-based prediction of volume of distribution. J Pharm Sci. 2002;91(1):129\u201356.","journal-title":"J Pharm Sci"},{"issue":"1","key":"1175_CR20","doi-asserted-by":"publisher","first-page":"667","DOI":"10.3109\/08982109409037065","volume":"4","author":"PK Working","year":"1994","unstructured":"Working PK, Newman MS, Huang SK, Mayhew E, Vaage J, Lasic DD. Pharmacokinetics, biodistribution and therapeutic efficacy of doxorubicin encapsulated in Stealth\u00ae liposomes (Doxil\u00ae). J Liposome Res. 1994;4(1):667\u201387.","journal-title":"J Liposome Res"},{"issue":"2","key":"1175_CR21","first-page":"79","volume":"9","author":"AH Silva","year":"2017","unstructured":"Silva AH, Lima E Jr, Mansilla MV, Zysler RD, Pisciotti MLM, Locatelli C, Siccardi M. A physiologically based pharmacokinetic model to predict the superparamagnetic iron oxide nanoparticles (SPIONs) accumulation in vivo. Eur J Nanomed. 2017;9(2):79\u201390.","journal-title":"Eur J Nanomed"},{"issue":"2","key":"1175_CR22","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1016\/j.jconrel.2005.03.030","volume":"107","author":"XB Xiong","year":"2005","unstructured":"Xiong XB, Huang Y, Lu WL, Zhang X, Zhang H, Nagai T, Zhang Q. Enhanced intracellular delivery and improved antitumor efficacy of doxorubicin by sterically stabilized liposomes modified with a synthetic RGD mimetic. J Control Release. 2005;107(2):262\u201375.","journal-title":"J Control Release"},{"key":"1175_CR23","unstructured":"DrugBank. Doxorubicin. Available at: https:\/\/go.drugbank.com\/drugs\/DB00997. Accessed 19 Apr 2022."},{"issue":"10","key":"1175_CR24","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.1002\/jps.2600731008","volume":"73","author":"T Terasaki","year":"1984","unstructured":"Terasaki T, Igax T, Sugiyama Y, Hanano M. Pharmacokinetic study on the mechanism of tissue distribution of doxorubicin: interorgan and interspecies variation of tissue-to-plasma partition coefficients in rats, rabbits, and guinea pigs. J Pharm Sci. 1984;73(10):1359\u201363.","journal-title":"J Pharm Sci"},{"issue":"4","key":"1175_CR25","first-page":"987","volume":"54","author":"A Gabizon","year":"1994","unstructured":"Gabizon A, Catane R, Uziely B, Kaufman B, Safra T, Cohen R, Barenholz Y. Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes. Can Res. 1994;54(4):987\u201392.","journal-title":"Can Res"},{"issue":"5","key":"1175_CR26","first-page":"2295","volume":"46","author":"A Rahman","year":"1986","unstructured":"Rahman A, Carmichael D, Harris M, Roh JK. Comparative pharmacokinetics of free doxorubicin and doxorubicin entrapped in cardiolipin liposomes. Can Res. 1986;46(5):2295\u20139.","journal-title":"Can Res"},{"issue":"5","key":"1175_CR27","doi-asserted-by":"publisher","first-page":"419","DOI":"10.2165\/00003088-200342050-00002","volume":"42","author":"A Gabizon","year":"2003","unstructured":"Gabizon A, Shmeeda H, Barenholz Y. Pharmacokinetics of pegylated liposomal doxorubicin. Clin Pharmacokinet. 2003;42(5):419\u201336.","journal-title":"Clin Pharmacokinet"},{"issue":"4","key":"1175_CR28","doi-asserted-by":"publisher","first-page":"15","DOI":"10.2165\/00003495-199700544-00005","volume":"54","author":"A Gabizon","year":"1997","unstructured":"Gabizon A, Martin F. Polyethylene glycol-coated (pegylated) liposomal doxorubicin. Drugs. 1997;54(4):15\u201321.","journal-title":"Drugs"},{"issue":"5","key":"1175_CR29","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1016\/j.nucmedbio.2009.02.004","volume":"36","author":"A Soundararajan","year":"2009","unstructured":"Soundararajan A, Bao A, Phillips WT, Perez R III, Goins BA. [186Re] Liposomal doxorubicin (Doxil): in vitro stability, pharmacokinetics, imaging and biodistribution in a head and neck squamous cell carcinoma xenograft model. Nucl Med Biol. 2009;36(5):515\u201324.","journal-title":"Nucl Med Biol"},{"issue":"5","key":"1175_CR30","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1007\/s00280-017-3278-9","volume":"79","author":"V Burade","year":"2017","unstructured":"Burade V, Bhowmick S, Maiti K, Zalawadia R, Jain D, Rajamannar T. Comparative plasma and tissue distribution of Sun Pharma\u2019s generic doxorubicin HCl liposome injection versus Caelyx\u00ae(doxorubicin HCl liposome injection) in syngeneic fibrosarcoma-bearing BALB\/c mice and Sprague-Dawley rats. Cancer Chemother Pharmacol. 2017;79(5):899\u2013913.","journal-title":"Cancer Chemother Pharmacol"},{"key":"1175_CR31","first-page":"5135","volume":"52","author":"SK Huang","year":"1992","unstructured":"Huang SK, Lee KD, Hong K, et al. Microscopic localization of sterically stabilized liposomes in colon carcinoma-bearing mice. Cancer Res. 1992;52:5135\u201343.","journal-title":"Cancer Res"},{"key":"1175_CR32","first-page":"3352","volume":"54","author":"F Yuan","year":"1994","unstructured":"Yuan F, Leunig M, Huang SK, et al. Microvascular permeability and interstitial penetration of sterically stabilized (Stealth) liposomes in a human tumor xenograft. Cancer Res. 1994;54:3352\u20136.","journal-title":"Cancer Res"},{"key":"1175_CR33","doi-asserted-by":"publisher","first-page":"133","DOI":"10.7326\/0003-4819-96-2-133","volume":"96","author":"SS Legha","year":"1982","unstructured":"Legha SS, Benjamin RS, Mackay B, et al. Reduction of doxorubicin cardiotoxicity by prolonged continuous intravenous infusion. Ann Intern Med. 1982;96:133\u20139.","journal-title":"Ann Intern Med"}],"container-title":["Drug Delivery and Translational Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13346-022-01175-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13346-022-01175-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13346-022-01175-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,8]],"date-time":"2022-08-08T13:58:06Z","timestamp":1659967086000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13346-022-01175-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,13]]},"references-count":33,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2022,9]]}},"alternative-id":["1175"],"URL":"https:\/\/doi.org\/10.1007\/s13346-022-01175-w","relation":{},"ISSN":["2190-393X","2190-3948"],"issn-type":[{"value":"2190-393X","type":"print"},{"value":"2190-3948","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,13]]},"assertion":[{"value":"27 April 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 May 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No ethical approval is required for this study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors have agreed with publication of the manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}